ERBB2 and triple-negative breast carcinoma: In HER2-positive and triple-negative breast cancer subtypes, lncRNA DLEU2 expression was highly detected in the progressive, stable, and partial treatment response groups, and lowest in patients who had a complete response to the treatment (Fig. 1D).